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Abstract
Rheumatoid arthritis (RA) is a refractory systemic autoimmune disease with chronic 
synovial inflammation. Sustained synovial inflammation leads to progressive destruc-
tion of bone and cartilage. Treatment to restore joints that have been destroyed irrevers-
ibly is not to be established yet even with the recent development of antirheumatic drugs 
and biological agents. Stage-specific embryonic antigen-3 (SSEA-3), a marker of human 
embryonic stem (ES) cell, acts as stem cells in the blood. SSEA-3 positive cells derived 
from RA synovial tissue have higher differentiating abilities than that of SSEA-3 negative 
cells and inhibitory effects on arthritis in collagen antibody-induced arthritis mice study. 
SSEA-3 positive cells derived from RA synovial tissue might have the inhibitory effect on 
arthritis and would be one of the cell sources for new RA treatment. The present manu-
script is a brief review of mesenchymal stem cells in RA and described with the potential 
of RA cell therapy by SSEA-3 positive cells based on our research.
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1. Introduction
Rheumatoid arthritis (RA) is a refractory systemic autoimmune disease with chronic syno-
vial inflammation. Sustained synovial inflammation leads to progressive destruction of 
bone and cartilage. In the pathogenesis of RA, activated T cells and antigen-presenting 
cells such as monocytes and macrophages produce inflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-2, IL-6, and interferon-γ (INF-γ). They 
promote release of inflammatory mediators, infiltration of inflammatory cells, production 
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of autoantibody, proliferation of the synovial cells, and activation of the osteoclasts, result-
ing in the bone and the cartilage destruction [1–3].
In the last few years, development of disease-modifying antirheumatic drugs (DMARDs) and 
biological agents targeting inflammatory cytokines has been major advances in the treatment of 
RA. Biological agents targeting inflammatory cytokines such as TNF-α, which has been shown to 
be a key factor in the pathology of RA, are effective for RA. These are known to improve disease 
activity and inhibit the progress of joint destruction. The best possible treatment goal for patients 
is clinical remission and consistently stopping continuing joint damage through erosions.
However, treatment to restore joints that have been destroyed irreversibly is not to be estab-
lished yet. Also, DMARDs or biological agents can have serious side effects affecting the 
blood, liver, or kidneys rarely. Therefore, a novel RA treatment that enables restoration of 
destroyed joints is needed. Use of mesenchymal stem cells (MSCs) derived from bone marrow 
as a biological method for repairing articular cartilage defects have been investigated [4–8]. 
We think that the treatment by thus autologous cells can overcome these problems.
2. Mesenchymal stem cells in RA synovial tissue
2.1. Multipotency
MSCs are self-renewing, multipotent progenitor cells with multilineage potential to differ-
entiate into various types of cells including chondrocytes, osteoblasts, and adipocytes [9–15]. 
While MSCs are most commonly isolated from bone marrow [13] and proliferate rapidly 
in vitro, they are also isolated from other tissues including adipose tissue [16], placenta [17], 
and umbilical cord blood [18]. Due to their accessibility and convenient expansion protocols, 
ethical dilemmas and risk of tumor formation, such as in ES cells and iPS cells, can also be 
avoided and therefore MSCs are easy to use in clinical application and have been recognized 
as promising candidates for cell therapy.
We investigated earlier the potential of chondrogenic differentiation of MSCs derived from 
bone marrow and synovial fluid in human osteoarthritis (OA) [19, 20]. Our study concluded 
that both bone marrow MSCs (BMMSCs) and synovial fluid MSCs (SFMSCs) had a potential 
of cell proliferation and chondrogenic differentiation. Both cells were fibroblast-like cells and 
had similar cell surface antigen in flow cytometry analysis, namely positive for CD13, CD44, 
and CD105 and negative for CD10, CD14, and CD45. However, aggrecan (AGG) mRNA 
expression in SFMSCs, which are traditionally associated with chondrogenic commitment, 
was a significant high compared to BMMSCs in vitro. According to other researches, SFMSCs 
are considered the same as synovial MSCs [21, 22]. Study of Sekiya et al. [23] reported that 
synovial MSCs are a candidate cell source for regenerative medicine of cartilage due to their 
high chondrogenic ability. They demonstrated that chondrogenic potentials of synovial MSCs 
between RA and OA patients were similar, as the weight of the pellet is a quantitative indica-
tor of the ability of MSCs to produce chondrogenesis in vitro. Therefore, autologous synovial 
MSCs can be expected in cartilage regeneration for RA patients. According to previous reports 
[24], there was a negative relationship between chondrogenic potential of synovial MSCs and 
magnitude of synovitis in RA, and some properties of synovial MSCs vary dependent on the 
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diseases patients have. Also, it was reported that chondrogenic potential in RA patients was 
inferior to that in OA patients. However, Jones et al. [24] reported that effective suppression 
of joint inflammation is necessary for the development of autologous MSC treatments aimed 
at cartilage regeneration in RA and synovial MSCs can be expected for RA patients with the 
inflammation well controlled as well as OA patients.
2.2. Immunosuppresive effect
Previous reports have suggested that synovial MSCs harvested from RA were capable of 
immunosuppression in vitro [24]. However, other reports have suggested that the immu-
nomodulatory function of synovial MSCs seems to be disturbed and causes an inefficacy 
due to various factors within RA microenvironment and as a result of a direct contact with 
inflammatory cells and cytokines [25]. In RA synovial tissue, synovial MSCs appear to play an 
important role in controlling the inflammation and immune hemostasis.
3. Stage-specific embryonic antigen-3 (SSEA-3) positive cells in RA 
synovial tissue
3.1. SSEA-3
Multilineage differentiating stress enduring (Muse) cells are a novel type of pluripotent stem 
cells and recently reported as adult human MSCs without introducing exogenous genes. They 
are present in various organs such as pancreas, dermis, umbilical cord, fat, liver, trachea, 
bone marrow, spleen [26–31] and are contained at a proportion of several percent in cul-
tured mesenchymal stem cells [26], 4–9% in human adipose tissue [27] and 1–2% in human 
skin fibroblasts [26]. Muse cells are able to differentiate into cells from all three embryonic 
germ layers both spontaneously and under media-specific induction. Also, Muse cells have 
a low tumor-forming ability compared with embryonic stem (ES) cells and a high efficiency 
of change to iPS cells by Yamanaka gene introduction [32]. They can migrate to damaged tis-
sues by intravenous injection in vivo, spontaneously differentiate into cells compatible with 
the targeted tissue, and contribute to tissue repair. Thus, Muse cells will be expected to play 
an important role in regenerative therapy by further studies. SSEA-3 is a marker of human 
embryonic stem cell. Muse cells are able to be isolated as SSEA-3 positive cells from cultured 
mesenchymal cells.
SSEA-3 positive cells are autologous cells and act as stem cells in the blood and also possess 
immunosuppression effects [28–31]. Therefore, they could be one of novel cell sources as cell ther-
apy in RA. We studied the possibility of SSEA-3 positive cells derived from RA synovial tissue.
3.2. SSEA-3 as cell therapy in RA
3.2.1. SSEA-3 positive cells in RA synovial tissue
We used synovial tissue harvested from 13 RA patients at the time of joint surgery in our 
hospital (Table 1) [33]. Diagnosis of RA for all patients was based on the American College of 
Rheumatology (ACR) criteria in 1987 [34] or the ACR/European League Against Rheumatism 
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(EULAR) classification criteria in 2010 [35]. Approval for this study was obtained from 
the Ethics of Human Experiments Committee at Hirosaki University Graduate School of 
Medicine, Hirosaki, Japan. Informed consent was obtained from all patients.
Immunohistochemical staining was performed to investigate the localization of SSEA-3 posi-
tive cells in RA synovial tissue. Harvested synovial tissue was immediately fixed in 4% para-
formaldehyde/PBS and embedded in paraffin in a usual manner. Rat monoclonal antibody 
specific for human SSEA-3 (Merck Millipore, Darmstadt, Germany) was used as a primary 
antibody. Immunoreactivity was detected by incubation with a biotinylated anti-rat IgG anti-
body (Vectastain ABC kit; Vector Laboratories, Burlingame, CA, USA), followed by streptavi-
din-biotin reaction (Vectastain ABC kit). Immunohistochemical staining for SSEA-3 showed a 
few positive cells in RA synovial tissue (Figure 1a–c).
Harvested synovial tissue was minced, digested with 3 mg/mL collagenase Type V (Wako Pure 
Chemical Industries: Osaka, Japan) for 3 hours at 37°C, and cultured in the αMEM (Sigma-Aldrich: 
Tokyo, Japan) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific: Waltham, MA, 
USA) and antibiotics (100 units/mL penicillin G and 100 μg/mL streptomycin) (Thermo Fisher 
Scientific) at 37°C in a 5% CO2 incubator. SSEA-3 positive cells were sorted by suspending 1 × 106 synovial cells at passage 2 in 100 ml FACS buffer containing 1 ml of EDTA, 5 ml of BSA, and 44 ml 
of FluoroBrite DMEM (Thermo Fisher Scientific, Waltham, MA, USA). Cells were collected by 
using antibody specific for SSEA-3, approximately 1% in cultured cells (Figure 1d).
SSEA-3 positive cells strongly expressed CD44, CD90, and CD105 and lacked CD34 (Figure 2) 
in flow cytometry assay. SSEA-3 negative cells were similar to positive cells in immunophe-
notype, but they weakly expressed CD105.
Pts. Age M/F Stage Class R/L Surgery
1 73 M IV III R total knee arthroplasty
2 45 F I II L arthroscopic synovectomy
3 78 M III I R total knee arthroplasty
4 82 F IV II R total knee arthroplasty
5 77 M IV II L total knee arthroplasty
6 84 F IV II R total knee arthroplasty
7 69 F III II R total elbow arthroplasty
8 77 F III II L total elbow arthroplasty
9 66 F IV II R 2nd, 4th PIP arthrodesis
10 69 F IV III L 1st IP arthrodesis
11 61 F IV II R wrist arthroplasty
12 62 F IV II R 1st IP arthrodesis
13 66 F III I L total hip arthroplasty
Pts, patients; M/F, male or female; R/L, right or left; PIP, proximal interphalangeal joint; IP, interphalangeal joint.
Table 1. Clinical data of patients with RA (n = 13) for this study.
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Histological staining after differentiation induction culture showed differentiation into osteo-
blasts, adipocytes, and chondrocytes from the cultured SSEA-3 positive cells (Figure 3). In all 
mRNA expression of alkaline phosphatase (ALP) and bone morphogenetic protein 2 (BMP2) 
for osteogenic differentiation, peroxisome proliferator-activated receptor gamma (PPARγ) for 
adipogenic differentiation and type II collagen (COL2A1), sex determining region Y (SRY)-
Box 9 (SOX9) and aggrecan (AGG) for chondrogenic differentiation, SSEA-3 positive cells 
showed higher gene expression level than SSEA-3 negative cells although there were indi-
vidual differences (Figure 4). These results indicate possibility of higher differentiation ability 
of SSEA-3 positive cells.
3.2.2. Inhibitory effect on arthritis
Collagen antibody-induced arthritis (CAIA) mice were established as the animal model for RA 
[36]. Induction of CAIA mice was performed on scid/scid mice, 7 weeks old (CLEA Japan), in 
which they were injected with 1.5 mg of 5-clone cocktail (arthrogen-CIA arthrogenic monoclo-
nal antibody (mAb), Chondrex, Redmond, WA) by intraperitoneal (IP) injection at Day 0. Fifty 
micrograms of lipopolysaccharide (LPS) (Chondrex) was injected by IP injection at Day 3. 3 × 104. 
SSEA-3 positive cells labeled with cell tracker green (CTG) (Thermo Fisher Scientific) were sus-
pended in PBS, filtered, then intravenously injected via the tail vein after the injection of LPS 
at Day 3. SSEA-3 negative cells labeled with CTG were used in the same procedure as control. 
Mice were scored for clinical arthritis; paws were assessed for signs of redness and  swelling. 
Figure 1. (a) RA synovial tissue. Hematoxylin and eosin (HE) staining. (b) Immunohistochemical staining specific for 
SSEA-3 in RA synovial tissue. (c) Magnified feature of (b). Bar = 100 mm. (d) Ratio of SSEA-3 positive cells in cultured 
cells derived from RA synovial tissue.
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Each paw was given a score of 0–4, giving a total maximum score of 16. (0, normal paw; 1, 
mild but definite redness and swelling in each joint of the digit or wrist/ankle; 2, moderate 
redness and swelling in two joints of the wrist/ankle with digit involvement; 3, severe redness 
and swelling in whole paw; 4, maximum inflammation within the wrist/ankle with many dig-
its involved) [37]. Figure 5a displays the arthritis score of CAIA mice in the both transplanted 
groups after mAb injection. The group transplanted with SSEA-3 positive cells (n = 3) con-
sisted of mice with intravenously transplanted SSEA-3 positive cells labeled with cell tracker 
green (CTG) seen in Figure 5b, while the group transplanted with SSEA-3 negative cells (n = 3) 
consisted mice with the transplanted SSEA-3 negative cells in the same procedure. Arthritis in 
the SSEA-3 negative cells group remained for 28 days, while arthritis score in the SSEA-3 posi-
tive cells group improved faster after peak inflammation (Figure 5a). There was a significant 
Figure 2. Representative flow cytometry analysis data.
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Figure 3. Multipotency of SSEA-3 positive cells derived from RA synovial cells. Osteogenesis was shown by alizarin 
red and alkaline phosphatase (ALP) staining. Adipogenesis was shown by oil red-O staining and chondrogenesis was 
shown by toluidine blue (TB) staining.
Figure 4. Real-time polymerase chain reaction (PCR) analysis. Results are reported as the mean of three independent 
experiments and the messenger RNA (mRNA) value of glyceraldehydes-3-phosphate-dehydrogenase (GAPDH) was set 
as an internal control. Osteogenesis was shown by the expression of ALP mRNA and BMP-2 mRNA, adipogenesis was 
shown by the expression of PPARγ mRNA and chondrogenesis was shown by the expression of COL2A1 mRNA, SOX9 
and AGG. Each data represents an average of three times. Note that the x-axis numbers represent patients in Table 1. 
The mRNA values of y-axis were arbitrary set.
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improvement in arthritis in the SSEA-3 positive cells group. On Day 5, CTG-labeled cells were 
detected in the synovial tissue (Figure 5c and d) and were still present on Day 28 (Figure 5e 
and f) in the group transplanted with SSEA-3 positive cells. Figure 5e shows representative 
joint in the group transplanted with SSEA-3 positive cells on Day 28 and Figure 5f shows 
SSEA-3 positive cells in synovial tissue in the immunohistochemical staining of Figure 5e. 
Figure 5g and h show the progression of joint destruction in the group transplanted with 
SSEA-3 negative cells on Day 28. CTG-labeled cells were not detected in other healthy organs 
on Day 28 by fluorescent microscopy (data not shown). These results indicate that SSEA-3 pos-
itive cells have the inhibitory effect on arthritis and systemic administration of them is safety.
4. Conclusions
In our study, SSEA-3 positive cells were detected in RA synovial tissue even under patho-
logical conditions such as RA. Although the synovial tissue we used was collected from 
various RA disease stages and surgical sites, SSEA-3 positive cells were detected with values 
of approximately 0.5–1% in all cultured SFMSCs. Collected SSEA-3 positive cells had higher 
gene expression level and differentiation ability in vitro compared with SSEA-3 negative cells 
Figure 5. (a) Arthritis score of CAIA mice after mAb injection. SSEA-3 (−) cells group consisted of mice transplanted with 
SSEA-3 negative cells. SSEA-3 (+) cells group consisted of mice transplanted with SSEA-3 positive cells. Both groups 
contained three mice. Each score shows average values of three mice and * means p < 0.05. The X-axis means the day 
from day 0 when the monoclonal antibody cocktail was administered. (b) Cell tracker green (CTG)-labeled SSEA-3 
positive cells (10X). (c, d and e, f) histology of joint of CAIA mouse after CTG-labeled SSEA-3 positive cells injections 
on day 5 and 28, respectively. Arrows shows CTG-labeled cells and positive cells for SSEA-3 in immunohistochemical 
staining. Bar = 100 mm. (g and h) representative histology of joint of CAIA mouse after CTG-labeled SSEA-3 negative 
cells injections on day 28. Bar = 100 mm.
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that were occupying most of mesenchymal stem cells. Wakao S., et al., reported that Muse 
and non-Muse cells had differentiation ability of osteocytes, chondrocytes, and adipocytes, 
while differentiation ability in non-Muse cells was lower [31]. We think that SSEA-3 positive 
cells in this study had a similar nature as Muse cells, considering also the results that SSEA-3 
positive cells strongly expressed CD105 in FACS analysis. SSEA-3 positive cells can be sys-
temically administered by intravenous administration like Muse cells and have possibility of 
differentiation into osteoblasts, adipocytes, and chondrocyte. These suggest the possibility of 
repairing degenerative cartilage and destroyed joints in RA. In the CAIA mice experiment, 
SSEA-3 positive cells that were systemically administered had an inhibitory effect on arthri-
tis. In the transplanted group consisting of mice transplanted with SSEA-3 positive cells, 
arthritis score quickly decreased after the onset of arthritis compared with SSEA-3 negative 
cells group. There were some previous studies on immunosuppressive effect of BMMSCs 
[38–40] and SFMSCs [24] as mentioned earlier. Especially, SFMSCs extracted from healthy 
subjects are able to inhibit T-cell proliferation [25]. However, immunomodulatory function 
of SFMSCs and SSEA-3 positive cells may be disturbed and cause an inefficacy of SFMSCs 
and SSEA-3 positive cells in inflammatory environment like uncontrolled RA [41]. In RA 
synovial tissue, fibroblast-like synoviocytes (FLS) are key players in the perpetuation of joint 
inflammation and destruction. The link between FLS and SFMSCs plays an important role in 
controlling the inflammation and immune hemostasis in RA. In our mice study, autologous 
SSEA-3 positive cells proliferated in vitro might have altered the balance of immune regula-
tion with FLS.
Our study suggests the possibility of inhibiting arthritis and joint destruction by SSEA-3 posi-
tive cells derived from synovial tissue in RA. Further study of SSEA-3 positive cells for clinical 
application in humans will lead to future development as a new treatment in RA.
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